SEC Filing Analysis: CORCEPT THERAPEUTICS INC

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer at Corcept Therapeutics has filed a notice of a proposed sale of $1.42 million in common stock, executed under a pre-existing 10b5-1 trading plan.
• Market Impact: The transaction is considered routine and is unlikely to have a material impact on the stock, given its small size relative to the company's market cap and its pre-planned nature.

Company Information

Field	Value
Company	CORCEPT THERAPEUTICS INC
Ticker Symbol	null
CIK	0001088856
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Guyer William
CIK	0001879013
Title/Position	Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-05
Transaction Code	null
Security Type	Common
Shares Involved	20000
Price Per Share	$71.1
Total Value	$1,422,000
Shares Owned After	null
Ownership Type	null

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,422,000
% of Market Cap	0.018%
Shares Transacted	20,000
% of Shares Outstanding	0.019%
Post-Transaction Ownership	Not specified
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $7.74 billion, this $1.42 million sale is negligible and falls well below thresholds for significance.
• Transaction Significance: The sale represents a tiny fraction of both the market cap (0.018%) and shares outstanding (0.019%), reinforcing its low materiality. The filing also shows a pattern of similar sales by the insider in prior months, suggesting a consistent, planned liquidation schedule.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Form 144 is a notice of intent to sell, not a completed sale. The transaction is pre-planned under a 10b5-1 plan and is immaterial in size, making any market reaction unlikely.

Volume & Sentiment

• Expected Volume Impact: Minimal. The number of shares is too small to significantly affect trading volume.
• Sentiment Indicator: Neutral. Pre-planned sales by executives are common for diversification and liquidity and are not typically viewed as a bearish signal.

Additional Context

Transaction Notes

• Special Circumstances: The filing indicates the sale is pursuant to a trading plan adopted on November 27, 2024. This provides a strong defense against claims of trading on non-public information and reduces the signal value of the sale.